eFFECTOR Therapeutics’ Lead Product Candidate, eFT508, Receives Orphan Designation from FDA for Treatment of Diffuse Large B-Cell Lymphoma

SAN DIEGO, March 9, 2017 – eFFECTOR Therapeutics today announced that its lead product candidate, eFT508, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin lymphoma. eFT508 is a potent, highly selective inhibitor of MNK1 and […]

eFFECTOR Therapeutics Appoints Jeremy Barton, M.D., as Chief Medical Officer

SAN DIEGO, September 15, 2016 – eFFECTOR Therapeutics, Inc., a biopharmaceutical company developing selective translation regulators for the treatment of cancer, today announced that Jeremy Barton, M.D., has joined eFFECTOR as chief medical officer. Dr. Barton brings a long and successful track record in oncology drug development to eFFECTOR, having held leadership positions at large […]

eFFECTOR Therapeutics to Present at the American Association for Cancer Research 2016 Annual Meeting

SAN DIEGO, March 18, 2016 – eFFECTOR Therapeutics, Inc., a biopharmaceutical company developing selective translation regulators for the treatment of cancer, today announced the preclinical profile of lead product candidate eFT508 will be presented at a special drug development track session titled “New Drugs on the Horizon 2” at the Annual Meeting of the American […]

eFFECTOR Therapeutics Increases its Series B Financing Round to $56M

SAN DIEGO, February 19, 2016 — eFFECTOR Therapeutics, Inc., a biopharmaceutical company developing selective translation regulators for the treatment of cancer, today announced it has increased its Series B financing to a total of $56M.

eFFECTOR Therapeutics Initiates Dosing in Phase 1/2 Clinical Trial of eFT508 in Solid Tumors

SAN DIEGO, January 6, 2016 – eFFECTOR Therapeutics, Inc., a biopharmaceutical company developing selective translation regulators for the treatment of cancer, today announced that dosing has begun in a Phase 1/2 dose-escalation and cohort-expansion study of eFT508 in patients with advanced solid tumors. eFT508 is the company’s potent, highly selective oral inhibitor of MNK1 and […]

eFFECTOR Therapeutics Raises $40 Million Series B Financing

SAN DIEGO, December 22, 2015 – eFFECTOR Therapeutics, a biopharmaceutical company developing translation regulators for the treatment of cancer, today announced that it has received $40 million in a Series B financing following the advancement of its lead program toward clinical trials. The financing was led by Altitude Life Science Ventures and joined by AbbVie Biotech Ventures and BioMed Ventures. […]

eFFECTOR Therapeutics Appoints Alana McNulty Chief Financial Officer

SAN DIEGO, Dec. 15, 2015 – eFFECTOR Therapeutics, Inc., a biopharmaceutical company developing selective translation regulators for the treatment of cancer, today announced that Alana McNulty has joined eFFECTOR as its full-time chief financial officer.

eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)

The poster titled “eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)” was presented by Kevin R. Webster, Ph.D., on December 5, 2015 at the 57th Annual 2015 American Society of Hematology (ASH) meeting in Orlando, FL.

Peer-Reviewed Study in Cell Validates eFFECTOR Therapeutics’ Novel Small-Molecule Approach to Cancer Treatment

SAN DIEGO, June 19, 2015 – eFFECTOR Therapeutics co-founder Davide Ruggero, Ph.D., has published ground-breaking research in the preeminent biomedical journal Cell which demonstrates preclinical promise for a cancer treatment approach that’s centered on selectively regulating the cell’s protein synthesis process, known as translation.

eFFECTOR Therapeutics Raises $45 Million in Series A Financing

San Diego, CA – May 20, 2013 – eFFECTOR Therapeutics, a newly established biopharmaceutical company, today announced the completion of a $45 million Series A financing.  eFFECTOR is focused on inventing and developing small molecule drugs to selectively regulate protein synthesis, also known as translation, with an initial emphasis on cancer.